Abstract: Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer patients to provide information regarding the genetic landscape of the cancer. It is emerging as an alternative and complementary diagnostic and prognostic tool to surgical biopsy in oncology. Liquid biopsy focuses on the detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in cancer patients. Liquid biopsy is expected to provide the necessary acceleratory force for the implementation of precision oncology in clinical settings by contributing an enhanced understanding of tumor heterogeneity and permitting the dynamic monitoring of treatment responses and genomic variations. However, widespread implementation of liquid biopsy based biomarker-driven therapy in the clinical practice is still in its infancy. Technological advancements have resolved many of the hurdles faced in the liquid biopsy methodologies but sufficient clinical and technical validation for specificity and sensitivity has not yet been attained for routine clinical implementation. This article provides a comprehensive review of the clinical utility of liquid biopsy and its effectiveness as an important diagnostic and prognostic tool in colorectal, breast, hepatocellular, gastric and lung carcinomas which were the five leading cancer related mortalities in 2018.

Keywords: liquid biopsy; circulating tumor cells (CTCs); circulating tumor DNA (ctDNA); exosomes; cancer diagnosis; cancer prognosis

1. Introduction

Decades of astounding cancer research has defined cancer to be a disease that involves mutations in the cell genome [1]. Random mutations generated due to the development of genomic instability in cancer cells is considered to be a prominent factor that could orchestrate and expedite the acquisition of various hallmarks of cancer such as sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis [2]. The GLOBOCAN 2018 has estimated the global cancer incidence and mortality to be at 18.1 million and 9.6 million cancer deaths respectively in 2018. Cancer accounted for being the second leading cause of death globally. Lung cancer (18.4%), colorectal cancer (9.2%), gastric cancer
(8.2%), hepatocellular cancer (8.2%) and breast cancer (6.6%) accounted for the top five leading causes of cancer-related deaths globally in 2018 [3].

The idea of precision oncology or precision medicine of cancer has emerged as a powerful clinical strategy in oncology with the objective of providing the most accurate and effective treatment to each cancer patient based on the genetic profile of cancer and the individual. Due to the genetic diversity and the rapidly changing dynamics of genomic profiles among cancer patients, better treatment efficacy could be attained if cancer therapeutics could shift from a concept of ‘one-size-fits-all’ approach to an individual level tailored treatment strategy [4]. Precision oncology is expected to emerge as an initiative to tackle various obstacles faced in cancer management, such as unexplained drug resistances, genomic heterogeneity of tumors and lack of appropriate methods for monitoring responses to therapies [5]. One of the prime challenges for the clinical implementation of precision oncology is to identify and detect molecular biomarkers that could predict the prognosis, sensitivity or resistance to a specific single agent or combination therapies, or specific therapy-associated adverse drug reactions [6]. In this scenario, liquid biopsy has been recently gaining widespread attention globally as an alternative/complementary to tissue biopsy in the era of “cancer theranostics” by being a minimally invasive prognostic and diagnostic tool that can assess the genetic landscape of various solid tumors.

The present study focuses on the clinical utility of liquid biopsy in the top five cancers that were the leading causes of cancer-related mortality in 2018 as per the GLOBOCAN 2018. The study was formulated after an exhaustive literature search from 165 articles collected through Google Search, PubMed and databases such as World Health Organisation (WHO) and www.fda.gov using the keywords ‘liquid biopsy’, ‘CTCs’, ‘ctDNA’, ‘exosomes’, ‘cancer diagnosis and cancer prognosis’ in combination with the Boolean operators “AND/OR.” Only the studies conducted in human subjects were considered for this report.

Liquid biopsy has emerged as a revolutionary technique that is providing new perspectives and dimensions to the field of medical oncology. It consists of the detection and isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes, as a source of genomic and proteomic information in patients with cancer [7]. Surgical biopsies (SB) are still considered to be the “gold standard” for diagnosis and treatment choice for diseases of genetic involvement such as cancer [8]. However, they are associated with inherent deficiencies such as:

- Limited accessibility of tumor tissue during tissue biopsy increases the chance of false-negative results [9].
- Lack of information regarding spatial and temporal heterogeneity of the tumor [10].
- Genetic landscape of the tumor might change due to the emergence of treatment-resistant sub clones which were in fewer numbers in the primary tumors [10].
- Problems due to logistic and technical complications such as tissue storage leads to false-positive results thereby affecting the treatment decision and patient care [11].
- Risk of adverse effects to the patient from the biopsy procedure [9].
- High total cost [12].

These disadvantages make tissue biopsy an unfeasible option for long term monitoring. Liquid biopsy, obtained with a routine blood draw, overcomes most of the limitations of tissues and can provide rapid detection of the tumor genetics including de novo and resistant mutations [13]. This technique involves the analysis of circulating tumor DNA, cell-free DNA, exosomes, RNA (mRNA and microRNA) and circulating tumor cells (CTCs) in the body fluids to determine the mutational status [14]. The US FDA approved the first liquid biopsy test on 1 June 2016 for analysis of EGFR mutations in Non-Small Cell Lung Carcinoma (NSCLC) patients using cobas EGFR Mutation Test v2. The test involves the detection of EGFR mutations in lung cancer patients whose tumors have the exon 18 (G719X) substitutions, exon 19 deletions, exon 20 insertions and substitutions (T790M, S768I) and exon 21 substitutions (L858R, L861Q) and is indicated to select patients who are candidates for EGFR
inhibitor therapy [15,16]. Table 1 provides a brief description of the advantages and disadvantages of liquid biopsy.

| Advantages                                                                 | Disadvantages                                                                 |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Helps in understanding the spatial and temporal heterogeneity of cancer [17]. | Lack of standardization of the techniques [23].                              |
| Requires only a small amount of blood (usually 6–10 mL of blood) [18].     | Sufficient clinical and technical validation is not yet attained, that is required for the routine clinical implementation [24]. |
| Minimally invasive [19].                                                  | In some cancers (e.g., lung cancers), the diagnosis and subtyping cannot be done by liquid biopsy and can be established by only histology [25]. |
| Real time monitoring for treatment responses and resistance could be performed by repeated analysis [21]. |                                                                       |
| Shorter turnaround time for genotyping mutations [18].                    |                                                                              |
| Aid precision oncology [22].                                              |                                                                              |

2. Molecular Tumor Targets of Liquid Biopsy

As mentioned above, the analysis of the genetic aberrations could be performed by liquid biopsy using biomarkers such as ctDNA, CTCs and exosomes.

2.1. ctDNA

DNA is constantly released into the circulation as fragments by apoptosis and necrosis of both cancerous and non-cancerous cells in our body [26,27]. If the DNA is released irrespective of the cell of origin, it is typically referred to as cfDNA and when it is released specifically by the cancerous cells, it is referred to as ctDNA. Mutations, copy number variations (CNVs), methylation changes or single-nucleotide variations (SNVs) harbored by ctDNA could be analyzed with high sensitivity and specificity. ctDNA is considered a better option when compared to archival tissue DNA in clinical scenarios where new biopsies are difficult to obtain [17]. cfDNA levels of healthy subjects range from 0 to 100 ng/mL of blood, with an average of 30 ng/mL, whereas in cancer patients they range from 0 to 1000 ng/mL of blood, with an average of 180 ng/mL [28]. In cancer patients, ctDNA represents only a small proportion of total cfDNA (varies from less than 0.1% to over 10%). This proportion depends upon the tumor burden, cancer stage, cellular turnover and response to therapy [29]. The amount of ctDNA increases with tumor growth [30]. It is estimated that patients with a tumor load of 100 g in size (≥3 × 10^{10} neoplastic cells) release 3.3% of the tumor DNA into the circulation on a daily basis [31]. ctDNA can be isolated from plasma, serum, ascites, breast milk, lymphatic and peritoneal fluids, bone marrow aspirates, urine, prostatic fluid, peritoneal lavage, sputum, cerebrospinal fluid, gastric juice, and biliary and stool samples [32].

2.2. CTCs

CTCs are intact tumor cells shed from both primary tumor sites and metastatic sites into the circulatory system [33]. The number of CTCs present in the blood is as low as one CTC per 10^6–10^7 leukocytes per milliliter of blood, with even lower numbers in the early stages of cancer [34]. The detection and isolation of the CTCs have been achieved by the technological advancements that studied and utilized the antigenic expression of the CTCs and their physical differences with the leukocytes [35]. CTCs represent a highly dynamic cell population, characterized by a high heterogeneity at the genetic, transcriptomic, proteomic and metabolomic levels [36]. The phenotypic and genotypic characteristics of CTCs can change during the course of the cancer by microenvironmental and therapeutic selective pressures [37]. As CTCs counts run in parallel with the tumor burden of the disease, they serve to be a more accurate method for the real time monitoring of cancers than many other commonly used soluble biomarkers [38–40].
2.3. Exosomes

Exosomes consist of a lipid bilayer which contains both transmembrane and nonmembrane proteins, as well as noncoding RNAs, mRNAs, and either single-stranded or double-stranded DNA [41]. Presence of exosomes was first reported in 1983 by Pan and Johnstone when culturing sheep reticulocytes at McGill University [42]. Exosomes are small membrane-enclosed vesicles 50–150 nm in size and 30–120 nm in diameter [43] which are actively discharged by most cells, including tumor cells [44] to extracellular space or biological fluids including serum [45], urine [46], breast milk, plasma, saliva [47], tears [48], pleural effusion [49], semen [50], amniotic fluid [51] and synovial fluid [52]. Studies have found that the analysis of double-stranded DNA [41] and RNA [53] content of exosomes provides details about the mutational status of the original cells as the architecture of exosomes protect RNA and miRNA from RNase catalytic activity thus providing accurate details of the primary tumor traits. A study has found that the integrin composition of exosomes promotes organotrophic metastasis [54] and thus the analysis of nucleic acids in exosomes can provide details regarding metastasis, tissue invasion and angiogenesis [55]. Isolation of exosomes from body fluids is carried out by technologies that are based on the biophysical properties (size, morphology, density), immunoaffinity capture or by precipitation method [56]. The clinical utility of exosomes as a tumor biomarker in cancer require further evidence from large clinical trials as most of the existing data are limited to small cohort studies [7].

3. Methods

Several methods have been proposed for the isolation and analysis of cfDNA, CTC and exosomes. cfDNA can be isolated using cfDNA isolation kits such as DNA isolation kit for mammalian blood (Boehringer Mannheim, now Roche Molecular Biochemicals, Mannheim, Germany), the QiaAmp blood kit (Qiagen, Germantown, MD, USA), and the Jetquick Blood Kit (Thermofischer, Waltham, MA, USA) which are available in the market [57]. Other methods used for cfDNA extraction include isolation with organic solvents such as phenol or chloroform [58] and the use of magnetic beads [59]. Isolation of cfDNA is followed by massive parallel sequencing [60,61] and digital genomic methods [62,63] for detection, quantification and molecular characterization of ctDNA fraction. CELLSEARCH® is an FDA approved test for capturing and enumerating CTCs. This method uses ferrofluid reagent, which consists of particles with a magnetic core surrounded by a polymeric layer coated with antibodies targeting the Epithelial cell adhesion molecule (EpCAM) antigen, for capturing CTCs [64]. The CTC chip, a microfluidic device is one of the techniques used for isolation of CTCs. This chip contains an array of microposts that contain anti-epithelial-cell-adhesion-molecule (EpCAM, also known as tumor-associated calcium signal transducer 1 (TACSTD1)) antibodies. These antibodies have an affinity towards the EpCAM, which is over-expressed by the carcinomas of lung, colorectal, breast, prostate, head and neck and hepatic origin [65] thereby making it a useful tool in the CTC isolation process with high specificity [66,67]. Apart from microchips, filtrating systems such as VyCAP or ISET (Isolation by SizE of Tumor cells) filtration [68] which can be enhanced by the bead-based capture [68] are also used for CTC isolation. Exosome isolation by conventional methods such as Western blotting and enzyme linked immunosorbent assay (ELISA) require large sample volume and extensive processing [69,70]. Hence methods such as nano-plasmonic sensor [71], BEAMing and Droplet Digital PCR Analysis (ddPCR) [72], microfluidic exosome analysis [73], microfluidic devices such as ExoChip [74], SOMAmer®-based assay technology [75] and surface plasmon resonance imaging [76] were developed to overcome these challenges.

Isolation is followed by PCR amplification and next generation sequencing (NGS). Hypermethylation, hypomethylation, deletions, amplifications, chromosomal rearrangement and mutations can be detected by PCR and NGS technologies [77] as depicted in Figure 1. Scorpion amplified refractory mutation system (ARMS), allele-specific quantitative PCR, PCR with peptide nucleic acid clamps, massively parallel sequencing, and ddPCR [78], COBAS EGFR test, competitive allele-specific PCR [79] and mutant specific PCR [80] are the widely used PCR techniques. NGS allows
the detection of multiple mutations in multiple genes in the following four steps: generation of short fragment DNA library, single fragment clonal amplification, massive parallel sequencing and data analysis [77]. In ultra-deep sequencing, the focus can be narrowed down on the clinically relevant gene panels and the mutations can be detected with high sensitivity and specificity [81,82]. AURA II studies have shown that the testing performance of NGS in detecting the EGFR mutation is relatively comparable to the PCR based and COBAS technologies [83]. NGS based EGFR mutation testing has shown to facilitate the determination of prognosis in patients with advanced NSCLC [84], monitoring genomic alterations [85–87], determining the resistance landscape to targeted therapies [88] and in predicting the response to therapy [89].

**Figure 1.** Procedure for performing liquid biopsy.

### 4. Significance of Liquid Biopsy in Various Cancers

Several studies have demonstrated that liquid biopsy could be used as a potential tool for the detection of genetic alterations in a wide variety of cancers. Studies have identified the presence of cancer-specific biomarkers such as EGFR, KRAS, ERBB2, EML4-ALK, CEA, SEPT9 in the body fluids of patients and have shown the possibility of reconstructing the tumor genomes from plasma DNA [90–94]. The clinical utility of other biomarkers in cancer is mentioned in Table 2. As the primary objective of the therapy is to prevent tumor progression, metastasis and recurrence, proper monitoring is required to check if the therapy fulfills the above requirement. Since liquid biopsy is feasible to repeat during follow-up, it can be used for monitoring therapeutic response and prognosis [95]. Here, we describe the clinical utility of liquid biopsy in several cancers.

#### 4.1. Colorectal Cancer

Colorectal cancer (CRC) is the third most common cancer worldwide and the second most prevalent cause of cancer deaths according to GLOBOCAN 2018 [96]. Mutations of genes such as KRAS [97], BRAF [98], TP53 [99], APC [100], CEA [101] and SEPT9 [102] are frequent in CRC. Detection of mutations in these genes by liquid biopsy is being studied as a cancer screening tool in populations at risk of cancer. Research studies have demonstrated that APC [29], BRAF and KRAS
mutations were identified in ctDNA with high sensitivity and specificity [103]. When compared to breast cancer or prostate cancer, colon cancer patients had very low levels of CTCs in external circulation making their detection difficult [31]. Liquid biopsy has been investigated as a method to analyse colon cancer staging as well as prognosis. TNM staging is significantly correlated with tumor traits in the blood samples of the patients [104]. Further, the depth of tumor invasion also showed a significant correlation with the presence of biomarkers [105]. Additional evidence validating the detection of ctDNA, CTCs, and cfDNA as a marker for early diagnosis in CRC should be obtained. Usually, ctDNA and CTC [105,106] levels are found to be associated with poor prognosis.

cfDNA concentration was increased in CRC patients and elevated cfDNA levels were also associated with poor prognosis [107]. Patients with three or more CTCs/7.5 mL are found to have a reduced survival [108]. Yet, a study by Bessa et al. found no correlation between CTC levels and prognosis in postoperative CRC patients [109]. An increase in cfDNA levels has been observed in patients who had a recurrence of mutation when compared to those with loss of mutation [110].

Table 2. Utility of liquid biopsy in various cancers.

| Sl.no | Cancer Type       | Genes                                           | Reference     |
|-------|-------------------|------------------------------------------------|---------------|
| 1.    | Colorectal cancer | KRAS, BRAF, TP53, APC, CEA, SEPT9               | [97–102]      |
| 2.    | Breast cancer     | HER2, BRCA1                                     | [111,112]     |
| 3.    | Lung cancer       | KRAS, EGFR, BRAF, ERBB2, PIK3CA, ALK, ROS1, RET, HER2, MET TP53, CTNNB1, PTEN, CDKN2A, ARID1A, CDK6, EGFR, MYC, BRAF, RAF1, FGFR1, CCNE1, PIK3CA, ERBB2/HER2 MUC1, CK19, HER2 TERT, CEA | [77,81,113–115] |
| 4.    | Hepatocellular cancer | MET, CDK6, EGFR, MYC, BRAF, RAF1, FGFR1, CCNE1, PIK3CA, ERBB2/HER2 | [113–115]     |
| 5.    | Gastric cancer    |                                                 | [116,117]     |

4.2. Breast Cancer

Breast cancer (BCa) is the second most common cancer worldwide and the fifth most prevalent cause of cancer deaths according to GLOBOCAN 2018 [96]. ctDNA of BCa patients contained the somatic SNVs, CNAs [90] thereby making it a useful tool for monitoring tumor burden [118], screening, understanding the drug response, determining prognosis [119–121] and detecting minimal residual disease [122]. Tumor size, lymph node metastasis, stage and grade were found to have a close relation with ctDNA among BCa patients [123–127]. cfDNA levels were found to be low in patients with non-metastatic breast disease when compared to malignant breast disease [128]. Studies have suggested that HER2 receptor status can be assessed using liquid biopsy technique. A retrospective study done on 107 CTC positive metastatic BCa patients depicted that liquid biopsy could be a useful method for revaluation of HER2 receptor status [111]. A case report by Tzeng et al. described that liquid biopsy was superior to IHC in determining the HER2 status [111]. Mayor et al. had reported that BRCA1 gene mutation could also be identified using liquid biopsy [112]. Several studies have shown the capacity of ctDNA in identifying the tumor-derived genomic alterations in BCa patients [130]. Dawson et al. demonstrated the presence of ctDNA and CTC in 97% and 87% of malignant BCa patients respectively [121]. A study reported a reduction in cfDNA integrity in metastatic BCa patients when compared to primary BCa patients [131]. Aceto et al. demonstrated that CTC clusters have up to 50 times increased metastatic potential when compared to individual CTCs [132]. Recurrence is a major problem in BCa. Liquid biopsy can be used as a potential tool for detecting tumor recurrence as tumor-specific copy number aberrations persist to about 12 years after diagnosis [129]. Liquid biopsy has been projected to be a potential diagnostic tool for determining the resistance to therapy [133].

4.3. Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the fourth most prevalent cause of cancer related deaths according to GLOBOCAN 2018 [96]. In all HCCs and
specifically in small tumors located near the diaphragm, liquid biopsy is considered to be a preferable option as the tumors are not easily accessed by fine needle biopsy. Many findings have reported that the occurrence of genetic mutations in plasma, serum and urine samples of patients with HCC [113]. Hepatocytes, cholangiocytes and hepatic stellate cells can act as both exosome releasing or targeting cells [134]. A study on 14 advanced HCC patients has shown that ctDNA can be utilized as a diagnostic marker in the detection of TP53, CTNNB1, PTEN, CDKN2A, ARID1A, MET, CDK6, EGFR, MYC, BRAF, RAF1, FGFR1, CCNE1, PIK3CA and ERBB2/HER2 mutations [113–115]. The role of exomes in the detection of the mutations in HCC is well established. The exosome content derived from HCC and non-tumor liver cells varied significantly. Exosomal mRNAs such as miR-21, miR-18a, miR-221, miR-222 and miR-224 serve as biomarkers in HCC [135–139]. Apart from exomes, CTCs are also found to be a suitable alternative. Tumor invasion, tumor size, differentiation status, the disease extent and survival [136], were significantly associated with CTC levels [140]. A major relation between the number of circulating cancer stem cells and intrahepatic and extrahepatic recurrence was observed, thus suggesting its role as a sovereign marker of survival [141]. Several studies have found that liquid biopsy was also found to be helpful in the early detection of HCC. DNA copy number aberrations were found in two HBV carriers without previous history of HCC during blood collection. Upon reassessment, two patients developed HCC, thereby shedding light on the evaluation of copy number aberrations in ctDNA as a screening tool for early HCC detection [142].

4.4. Gastric Cancer

Gastric cancer (GC) is the fifth most common cancer worldwide and the third most prevalent cause of cancer deaths according to GLOBOCAN 2018 [96]. Ling et al. reported that methylated XAF1 DNA was found in 69.8% (141/202) of GC patients and none in healthy individuals, thereby serving as a potential diagnostic and prognostic marker [143]. A study by Park et al. [144] reported a high plasma MYC/GAPDH ratio in GC patients when compared to healthy individuals. Kang et al. [145] demonstrated the significance of plasma hTERT mRNA as a potential diagnostic and prognostic marker in GC. CTCs are found to be effective in the detection of cancer-specific modifications such as altered expression of non-coding RNAs (e.g., miRNAs) in GC [146]. Studies have reported a lower overall survival rate in metastatic GC patients with higher CTC levels [147,148]. Results of a study that was conducted by Shoda et al. to detect HER2 amplification in cfDNA using RQ-PCR showed that cfDNA could be used as a significant therapeutic biomarker in the diagnosis and assessment of HER2 status [149]. Shoda et al. demonstrated a correlation between plasma and tissue HER2 amplification ratios by ddPCR [116]. Wu et al. [117] have shown that simultaneous sensitivity assay of the combination of markers such as TERT, CK19, CEA and MUC1 using a high-throughput colorimetric membrane array provides a platform for assessing the overall survival and postoperative recurrence/metastasis. Mimori et al. [150] demonstrated that membrane MT1-MMP mRNA levels in the peripheral blood serves as a prognostic indicator for determining recurrence and distant metastasis. Programmed death-ligand 1 (PD-L1) mRNA expression in the blood of advanced GC patients is significantly higher than that of early GC patients, suggesting its utility in assessing the prognosis [151]. The PD-L1 expression significantly correlated with the depth of invasion, metastasis and stage of cancer.

4.5. Lung Cancer

Lung cancer (LC) is the most common cancer worldwide and the most prevalent cause of cancer deaths according to GLOBOCAN 2018 [96]. Several genomic alterations have been identified in advanced LC patients using liquid biopsy that could aid in the determination of prognosis [152]. Couraud et al. have shown the utility of liquid biopsy based on detection of EGFR, KRAS, BRAF, ERBB2, PIK3CA mutations using cfDNA [81,153]. The study by Paweletz et al. demonstrated the detection of ALK, ROS1, and RET rearrangements, HER2 insertions, and MET amplification in patients with advanced NSCLC [77]. Newman et al. demonstrated that cfDNA levels in LC patients significantly correlated with CT and PET measured tumor volume. This study also revealed a correlation between
ctDNA levels and tumor volume [30]. Liquid biopsy also serves as a guiding tool for estimating the response of targeted therapy [154]. ctDNA levels can be utilized in tracking the subclonal nature of NSCLC relapse and metastasis [155]. Sozzi et al. showed that higher plasma DNA levels are associated with reduced 5-year survival [156]. The CTC count was found to be helpful in the determination of prognosis and survival time [157]. Multiple studies have demonstrated that patients with high levels of CTCs at initial diagnosis or after one cycle of chemotherapy showed a poor LC prognosis [158]. CTCs could serve as a surrogate marker of distant metastasis in patients with primary LC [159]. Meta-analysis of 12 randomized control trials has shown that the presence of KRAS mutation correlated well with the lower survival rate in NSCLC patients [160]. However, another study conducted by Camps et al. on patients with complex NSCLC demonstrated no relationship between KRAS mutation and prognosis [161]. Recurrence of LC has been observed in patients who had detectable levels of CTCs in their blood [162]. cfDNA is now proposed to be a useful tool in determining resistance to therapy [163].

5. Conclusions

The utilization of CTCs, ctDNA and exosomes as potential biomarkers for cancer theranostics is an emerging area with a strong potential for clinical utility. Liquid biopsy is emerging as a minimally invasive, repeatable and inexpensive method for accessing the tumor DNA, understanding the tumor heterogeneity, monitoring therapeutic effectiveness, prognosis, acquired resistance to therapy and disease resistance in cancer. Further large scale studies should be conducted to validate the process and assess its clinical utility in different populations. Currently, liquid biopsies have limited applications in clinical practice, but its versatility and advantages put forward its application as a promising diagnostic and prognostic tool for precision oncology.

Author Contributions: Conceptualization, R.A.M. and R.V.S.V.; Writing—Original draft preparation, R.A.M., R.V.S.V. and B.S.R.; Writing—Review and editing, R.A.M., R.V.S.V., B.S.R., L.T., M.R., J.K. and K.U.; Supervision, M.R.

Funding: The APC was funded by Manipal Academy of Higher Education, Manipal.

Acknowledgments: We are thankful to TMA Pai endowment chair in “Translational Research” to M.R and TMA Pai Ph.D. Scholarship to LT from MAHE, Manipal.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70. [CrossRef]
2. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [CrossRef]
3. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
4. Shin, S.H.; Bode, A.M.; Dong, Z. Precision medicine: The foundation of future cancer therapeutics. NPJ Precis. Oncol. 2017, 1, 12. [CrossRef] [PubMed]
5. Collins, F.S.; Varmus, H. A New Initiative on Precision Medicine. N. Engl. J. Med. 2015, 372, 793–795. [CrossRef]
6. Bailey, A.M.; Mao, Y.; Zeng, J.; Holla, V.; Johnson, A.; Brusco, L.; Chen, K.; Mendelsohn, J.; Routbort, M.J.; Mills, G.B.; et al. Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps. Disov. Med. 2014, 17, 101–114. [PubMed]
7. Palmirotta, R.; Lovero, D.; Cafforio, P.; Felici, C.; Mannavola, F.; Pelle, E.; Quaresmini, D.; Tucci, M.; Silvestris, F. Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Ther. Adv. Med. Oncol. 2018, 10, 175883918794630. [CrossRef] [PubMed]
8. Domínguez-Vigil, I.G.; Moreno-Martinez, A.K.; Wang, J.Y.; Roehrl, M.H.A.; Barrera-Saldaña, H.A. The dawn of the liquid biopsy in the fight against cancer. Oncotarget 2017, 9, 2912–2922. [CrossRef] [PubMed]
51. Keller, S.; Rupp, C.; Stoeck, A.; Runz, S.; Fogel, M.; Lugert, S.; Hager, H.-D.; Abdel-Bakky, M.S.; Gutwein, P.; Altevogt, P. CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int.** 2007, 72, 1095–1102. [CrossRef]
52. Skriner, K.; Adolph, K.; Jungblut, P.R.; Burmester, G.R. Association of citrullinated proteins with synovial exosomes. *Arthritis Rheum.* 2006, 54, 3809–3814. [CrossRef]
53. Cheng, L.; Sharples, R.A.; Scicluna, B.J.; Hill, A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *J. Extracell. Vesicles** 2014, 3, 23743. [CrossRef]
54. Hoshino, A.; Costa-Silva, B.; Shen, T.-L.; Rodrigues, G.; Hashimoto, A.; Mark, M.T.; Molina, H.; Kohsaka, S.; Di Giannatale, A.; Ceder, S.; et al. Tumor exosome integrins determine organotropic metastasis. *Nature** 2015, 527, 329–335. [CrossRef]
55. Salma, K.; Jessica, J.; Joon, P.; Nathan, W.; David, T.; Jonathan, A.; May, A.V.M. The Application of Membrane Vesicles for Cancer Therapy. In *Advances in Cancer Therapy*; InTech: London, UK, 2012.
56. Li, P.; Kaslan, M.; Lee, S.H.; Yao, J.; Gao, Z. Progress in Exosome Isolation Techniques. *Theranostics* 2017, 7, 789–804. [CrossRef]
57. Xue, X.; Teare, M.D.; Holen, I.; Zhu, Y.M.; Woll, P.J. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. *Clin. Chim. Acta** 2009, 404, 100–104. [CrossRef]
58. Jen, J.; Wu, L.; Sidransky, D. An Overview on the Isolation and Analysis of Circulating Tumor DNA in Plasma and Serum. *Ann. N. Y. Acad. Sci* 2000, 906, 8–12. [CrossRef]
59. Stemmer, C.; Beau-Faller, M.; Pencreac’h, E.; Guerin, E.; Schneider, A.; Jaqmin, D.; Quoix, E.; Gaub, M.-P.; Oudet, P. Use of Magnetic Beads for Plasma Cell-free DNA Extraction: Toward Automation of Plasma DNA Analysis for Molecular Diagnostics. *Clin. Chem.* 2003, 49, 1953–1955. [CrossRef]
60. Ignatiadis, M.; Dawson, S.J. Circulating tumor cells and circulating tumor DNA for precision medicine: Dream or reality? *Ann. Oncol.* 2014, 25, 2304–2313. [CrossRef]
61. Haber, D.A.; Velculescu, V.E. Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. *Cancer Discov.* 2014, 4, 650–661. [CrossRef]
62. Hindson, B.J.; Ness, K.D.; Masquelier, D.A.; Belgrader, P.; Heredia, N.J.; Makarewicz, A.J.; Bright, I.J.; Lucero, M.Y.; Hiddessen, A.L.; Legler, T.C.; et al. High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number. *Anal. Chem.* 2011, 83, 8604–8610. [CrossRef]
63. Pekin, D.; Skhiri, Y.; Baret, J.-C.; Corre, D.L.; Mazutis, L.; Salem, C.B.; Millot, F.; Harrak, A.E.; Hutchison, J.B.; Larson, J.W.; et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. *Lab Chip** 2011, 11, 2156–2166. [CrossRef]
64. Su, D.W.; Nieva, J. Biophysical technologies for understanding circulating tumor cell biology and metastasis. *Transl. Lung Cancer Res.* 2017, 6, 473–485. [CrossRef]
65. Went, P.T.H.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. *Hum. Pathol.* 2004, 35, 122–128. [CrossRef]
66. Sequist, L.V.; Nagrath, S.; Toner, M.; Haber, D.A.; Lynch, T.J. The CTC-Chip: An exciting new tool to detect circulating tumor cells in lung cancer patients. *J. Thorac. Oncol.* 2009, 4, 281–283. [CrossRef]
67. De Wit, S.; van Dalum, G.; Lenerferink, A.T.M.; Tibbe, A.G.J.; Hiltermann, T.J.N.; Groen, H.J.M.; van Rijn, C.J.M.; Terstappen, L.W.M.M. The detection of EpCAM+ and EpCAM− circulating tumor cells. *Sci. Rep.* 2015, 5, 12270. [CrossRef]
68. Sun, N.; Li, X.; Wang, Z.; Li, Y.; Pei, R. High-purity capture of CTCs based on micro-beads enhanced isolation by size of epithelial tumor cells (ISET) method. *Biosens. Bioelectron.* 2018, 102, 157–163. [CrossRef]
69. Simpson, R.J.; Lim, J.W.; Moritz, R.L.; Mathivanan, S. Exosomes: Proteomic insights and diagnostic potential. *Expert Rev. Proteom.* 2009, 6, 267–283. [CrossRef]
70. Taylor, D.D.; Zacharias, W.; Gercel-Taylor, C. Exosome Isolation for Proteomic Analyses and RNA Profiling. In *Serum/Plasma Proteomics*; Humana Press: New York, NY, USA, 2011; pp. 235–246.
71. Im, H.; Shao, H.; Park, Y.I.; Peterson, V.M.; Castro, C.M.; Weissleder, R.; Lee, H. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. *Nat. Biotechnol.* 2014, 32, 490–495. [CrossRef]
72. Chen, W.W.; Balaj, L.; Liau, L.M.; Samuels, M.L.; Kotsopoulos, S.K.; Maguire, C.A.; LoGuidice, L.; Soto, H.; Garrett, M.; Zhu, L.D.; et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. *Mol. Ther. Nucleic Acids* 2013, 2, e109. [CrossRef]
73. He, M.; Crow, J.; Roth, M.; Zeng, Y.; Godwin, A.K. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. *Lab Chip* 2014, 14, 3773–3780. [CrossRef]

74. Kanwar, S.S.; Dunlay, C.J.; Simeone, D.M.; Nagrath, S. Microfluidic device (ExoChip) for On-Chip isolation, quantification and characterization of circulating exosomes. *Lab Chip* 2014, 14, 1891–1900. [CrossRef]

75. Webber, J.; Stone, T.C.; Katilius, E.; Smith, B.C.; Gordon, B.; Mason, M.D.; Tabi, Z.; Brewis, I.A.; Clayton, A. Proteomics Analysis of Cancer Exosomes Using a Novel Modified Aptamer-based Array (SOMAscanTM) Platform. *Mol. Cell. Proteom.* 2014, 13, 1050–1064. [CrossRef]

76. Zhu, L.; Wang, K.; Cui, J.; Liu, H.; Bu, X.; Ma, H.; Wang, W.; Gong, H.; Lausted, C.; Hood, L.; et al. Label-Free Quantitative Detection of Tumor-Derived Exosomes through Surface Plasmon Resonance Imaging. *Anal. Chem.* 2014, 86, 8857–8864. [CrossRef]

77. Paweletz, C.P.; Sacher, A.G.; Raymond, C.K.; Alden, R.S.; O’Connell, A.; Mach, S.L.; Kuang, Y.; Gandhi, L.; Kirschmeier, P.; English, J.M.; et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. *Clin. Cancer Res.* 2016, 22, 915–922. [CrossRef]

78. Levy, B.; Hu, Z.I.; Cordova, K.N.; Close, S.; Lee, K.; Becker, D. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. *Oncologist* 2016, 21, 1121–1130. [CrossRef]

79. Ashida, A.; Sakaizawa, K.; Mikoshiba, A.; Uhara, H.; Okuyama, R. Quantitative Analysis of the BRAFV600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. *Int. J. Clin. Oncol.* 2016, 21, 981–988. [CrossRef]

80. Mastoraki, S.; Strati, A.; Tzankiou, E.; Chimonidou, M.; Politaki, E.; Voutsina, A.; Psyrri, A.; Georgoulas, V.; Lianidou, E. ESRI Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. *Clin. Cancer Res.* 2018, 24, 1500–1510. [CrossRef]

81. Couraud, S.; Vaca-Paniagua, F.; Villar, S.; Oliver, J.; Schuster, T.; Blanché, H.; Girard, N.; Trédaniel, J.; Guilleminault, L.; Gervais, R.; et al. Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002. *Clin. Cancer Res.* 2014, 20, 4613–4624. [CrossRef]

82. Jenkins, S.; Yang, J.C.-H.; Ramalingam, S.S.; Yu, K.; Patel, S.; Weston, S.; Hodge, R.; Cantarini, M.; Jänne, P.A.; Mitsudomi, T.; et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. *J. Thorac. Oncol.* 2017, 12, 1061–1070. [CrossRef]

83. Zhao, Y.; Gong, J.; Ma, W.; Banks, K.; Wen, H.; Moore, E.H.; Lanman, R.; Li, T. JCES01.10 Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer. *J. Thorac. Oncol.* 2017, 12, S234. [CrossRef]

84. Uchida, J.; Imamura, F.; Kukita, Y.; Oba, S.; Kumagai, T.; Nishino, K.; Inoue, T.; Kimura, M.; Kato, K. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. *Cancer Sci.* 2016, 107, 353–358. [CrossRef] [PubMed]

85. Zhou, Q.; Yang, J.-J.; Chen, Z.-H.; Zhang, X.-C.; Yan, H.-H.; Xu, C.-R.; Su, J.; Chen, H.-J.; Tu, H.-Y.; Zhong, W.-Z.; et al. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. *J. Hematol Oncol.* 2016, 9, 86. [CrossRef] [PubMed]

86. Ihuegbu, N.; Banks, K.C.; Fairclough, S.R.; Zill, O.A.; Chudova, D.; Lanman, R.B.; Blakely, C.M. Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors. *J. Clin. Oncol.* 2016, 34, e20643. [CrossRef]

87. Chabon, J.J.; Simmons, A.D.; Lovejoy, A.F.; Esfahani, M.S.; Newman, A.M.; Haringsma, H.J.; Kurtz, D.M.; Stehr, H.; Scherer, F.; Karlovich, C.A.; et al. Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat. Commun.* 2016, 7, 11815. [CrossRef] [PubMed]

88. Karlovich, C.; Goldman, J.W.; Sun, J.-M.; Mann, E.; Sequist, L.V.; Konopa, K.; Wen, W.; Angenendt, P.; Horst, L.; Spigel, D.; et al. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). *Clin. Cancer Res.* 2016, 22, 2386–2395. [CrossRef] [PubMed]
Wang, J.-Y.; Wu, C.-H.; Lu, C.-Y.; Hsieh, J.-S.; Wu, D.-C.; Huang, S.-Y.; Lin, S.-R. Molecular detection of
Thierry, A.R.; Mouliere, F.; El Messaoudi, S.; Mollevi, C.; Lopez-Crapez, E.; Rolet, F.; Gillet, B.; Gongora, C.;
Pietrantonio, F.; Biondani, P.; Perrone, F.; Bartolomeo, M.D.; Pacifici, M.; Milione, M.; Melotti, F.; Maggi, C.;
Bedin, C.; Enzo, M.V.; Bianco, P.D.; Pucciarelli, S.; Nitti, D.; Agostini, M. Diagnostic and prognostic role of
carcinoembryonic Antigen.
Hartminger, J.E.; Kotasek, D.; Sage, R.E.; Eaton, M.C.; Pascoe, V.H.; Dobrovic, A. Detection of circulating
Lefebure, B.; Charbonnier, F.; Fiore, F.; Tuech, J.; Pessot, F.; Michot, F.; Michel, P.; Frebourg, T. Prognostic Value of
Ann. Intern. Med.
Fletcher, R.H. Carcinoembryonic Antigen.
Palacio-R
Neumann, J.; Zeindl-Eberhart, E.; Kirchner, T.; Jung, A. Frequency and type of KRAS mutations in routine
Brooks, J.D. Translational genomics: The challenge of developing cancer biomarkers.
Heitzer, E.; Auer, M.; Ulz, P.; Geigl, J.B.; Speicher, M.R. Circulating tumor cells and DNA as liquid biopsies.
Globocan 2018 Source: Globocan 2018. Available online: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf (accessed on 2 January 2019).
Cancer Res.
Nature
Oncology
Gastroenterolog
Clin. Cancer Res.
Clin. Cancer Res.
Cell. Mol. Biol. (Noisy-le-grand)
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
Clin. Cancer Res.
109. Bessa, X.; Piñol, V.; Castellvi-Bel, S.; Piazzuelo, E.; Lacy, A.M.; Elizalde, J.I.; Piqué, J.M.; Castells, A. Prognostic Value of Postoperative Detection of Blood Circulating Tumor Cells in Patients with Colorectal Cancer Operated on For Cure. *Ann. Surg.* 2003, 237, 368–375. [CrossRef]

110. Spindler, K.-L.G.; Pallisgaard, N.; Andersen, R.E.; Jakobsen, A. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. *Int. J. Cancer* 2014, 135, 2215–2222. [CrossRef]

111. Wallwiener, M.; Hartkopf, A.D.; Riethdorf, S.; Nees, J.; Sprick, M.R.; Schönfisch, B.; Taran, F.-A.; Heil, J.; Sohn, C.; Pantel, K.; et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: A retrospective study in 107 patients. *BMC Cancer* 2015, 15, 403. [CrossRef]

112. Mayor, P.; Gay, L.M.; Lele, S.; Elvin, J.A. BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. *Gynecol. Oncol. Rep.* 2017, 21, 57–60. [CrossRef]

113. Lin, S.Y.; Dhillon, V.; Jain, S.; Chang, T.-T.; Hu, C.-T.; Lin, Y.-J.; Chen, S.-H.; Chang, K.-C.; Song, W.; Yu, L.; et al. A Locked Nucleic Acid Clamp-Mediated PCR Assay for Detection of a p53 Codon 249 Hotspot Mutation in Urine. *J. Mol. Diagn.* 2011, 13, 474–484. [CrossRef]

114. Hosny, G.; Farahat, N.; Tayel, H.; Hainaut, P. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. *Cancer Lett.* 2008, 264, 201–208. [CrossRef]

115. Jackson, P.E.; Qian, G.-S.; Friessen, M.D.; Zhu, Y.-R.; Lu, P.; Wang, J.-B.; Wu, Y.; Kensler, T.W.; Vogelstein, B.; Groopman, J.D. Specific p53 Mutations Detected in Plasma and Tumors of Hepatocellular Carcinoma Patients by Electrospray Ionization Mass Spectrometry. *Cancer Res.* 2001, 61, 33–35.

116. Shoda, K.; Ichikawa, D.; Fujita, Y.; Masuda, K.; Hiramoto, H.; Hamada, J.; Arita, T.; Konishi, H.; Komatsu, S.; Shiozaki, A.; et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer* 2017, 20, 126–135. [CrossRef]

117. Wu, C.-H.; Lin, S.-R.; Yu, F.-J.; Wu, D.-C.; Pan, Y.-S.; Hsieh, J.-S.; Huang, S.-Y.; Wang, J.-Y. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. *Int. J. Cancer* 2011, 149, 373–379. [CrossRef]

118. Wang, R.; Li, X.; Zhang, H.; Wang, K.; He, J. Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. *Oncotarget* 2017, 8, 75742–75755. [CrossRef]

119. Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J. Clin. Oncol.* 2008, 26, 3213–3221. [CrossRef]

120. Iqbal, S.; Vishnubhatla, S.; Raina, V.; Sharma, S.; Gogia, A.; Deo, S.S.V.; Mathur, S.; Shukla, N.K. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. *Springerplus* 2015, 4, 265. [CrossRef]

121. Dawson, S.J.; Tsui, D.W.Y.; Murtaza, M.; Biggs, H.; Rueda, O.M.; Chin, S.-F.; Dunning, M.J.; Gale, D.; Forshew, T.; Mahler-Araujo, B.; et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. *N. Engl. J. Med.* 2013, 368, 1199–1209. [CrossRef]

122. Garcia-Murilllas, I.; Schiavon, G.; Weigelt, B.; Ng, C.; Hreibien, S.; Cutts, R.J.; Cheang, M.; Osin, P.; Nerurkar, A.; Kozarewa, I.; et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. *Sci. Transl. Med.* 2015, 7, 302ra133. [CrossRef]

123. Silva, J.M.; Silva, J.; Sanchez, A.; Garcia, J.M.; Dominguez, G.; Provencio, M.; Sanfuentes, L.; Jareño, E.; Colas, A.; España, P.; et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. *Clin. Cancer Res.* 2002, 8, 3761–3766.

124. Phallen, J.; Sausen, M.; Adleff, V.; Leal, A.; Hruban, C.; White, J.; Anagnostou, V.; Fiksel, J.; Cristiano, S.; Papp, E.; et al. Direct detection of early-stage cancers using circulating tumor DNA. *Sci. Transl. Med.* 2017, 9, eaan2415. [CrossRef]

125. Catarino, R.; Ferreira, M.M.; Rodrigues, H.; Coelho, A.; Nogal, A.; Sousa, A.; Medeiros, R. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. *DNA Cell Biol.* 2008, 27, 415–421. [CrossRef]

126. Huang, Z.H.; Li, L.H.; Hua, D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. *Cancer Lett.* 2006, 243, 64–70. [CrossRef]
127. Kohler, C.; Radpour, R.; Barekati, Z.; Asadollahi, R.; Bitzer, J.; Wight, E.; Bürki, N.; Diesch, C.; Holzgreve, W.; Zhong, X.Y. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer Res. 2009, 8, 105. [CrossRef]
128. Zanetti-Dällenbach, R.; Wight, E.; Fan, A.X.-C.; Lapaire, O.; Hahn, S.; Holzgreve, W.; Zhong, X.Y. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res. 2008, 28, 921–925.
129. De Mattos-Arruda, L.; Weigelt, B.; Cortes, J.; Won, H.H.; Ng, C.K.Y.; Nuciforo, P.; Bidard, F.C.; Aura, C.; Saura, C.; Peg, V.; et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann. Oncol. 2014, 25, 1729–1735. [CrossRef]
130. Aceto, N.; Bardia, A.; Miyamoto, D.T.; Donaldson, M.C.; Wittner, B.S.; Spencer, J.A.; Yu, M.; Pely, A.; Pantel, K.; et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 2014, 146, 163–174. [CrossRef]
131. Madhavan, D.; Wallwiener, M.; Bents, K.; Zucknick, M.; Nees, J.; Schott, S.; Cuk, K.; Riethdorf, S.; Trumpp, A.; Pantel, K.; et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 2014, 146, 163–174. [CrossRef]
132. Janku, F.; Angenendt, P.; Tsimberidou, A.M.; Fu, S.; Naing, A.; Falchook, G.S.; Hong, D.S.; Holley, V.R.; Cabrillo, G.; Wheler, J.J.; et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 2015, 6, 12809–12821. [CrossRef]
133. Labgaa, I; Villanueva, A. Liquid Biopsy in Liver Cancer. Discov. Med. 2015, 19, 263–273.
134. Masyuk, A.I.; Masyuk, T.V.; LaRusso, N.F. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J. Hepatol. 2013, 59, 621–625. [CrossRef]
135. Fan, S.T.; Yang, Z.F.; Ho, D.W.Y.; Ng, M.N.P.; Yu, W.C.; Wong, J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study. Ann. Surg. 2011, 254, 569–576. [CrossRef]
136. Jiang, P.; Chan, C.W.M.; Chan, K.C.A.; Cheng, S.H.; Wong, J.; Wong, V.W.S.; Wong, G.L.H.; Chan, S.L.; Mok, T.S.K.; Chan, H.L.Y.; et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. USA 2015, 112, E1317–E1325. [CrossRef]
137. Ling, Z.-Q.; Lv, P.; Lu, X.-X.; Yu, J.-L.; Han, J.; Ying, L.-S.; Zhu, X.; Zhu, W.-Y.; Fang, X.-H.; Wang, S.; et al. Circulating Methylation of XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS ONE 2013, 8, e67195. [CrossRef]
138. Kogure, T.; Lin, W.-L.; Yan, I.K.; Braconi, C.; Patel, T. Inter-cellular nanovesicle mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54, 1237–1248. [CrossRef]
139. Wei, J.; Lv, L.; Wan, Y.; Cao, Y.; Li, G.; Lin, H.; Zhou, R.; Shang, C.Z.; Cao, J.; He, H.; et al. Vps4A Functions as a Tumor Suppressor by Regulating the Secretion and Uptake of Exosomal MicroRNAs in Human Hepatoma Cells. Hepatology 2015, 61, 1284–1294. [CrossRef]
140. Wang, H.; Hou, L.; Li, A.; Duan, Y.; Gao, H.; Song, X. Expression of Serum Exosomal MicroRNA-21 in Human Hepatocellular Carcinoma. Biomed. Res. Int. 2014, 2014. [CrossRef]
141. Sohn, W.; Kim, J.; Kang, S.H.; Yang, S.R.; Cho, J.-Y.; Cho, H.C.; Shim, S.G.; Paik, Y.-H. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp. Mol. Med. 2015, 47, e184. [CrossRef]
142. Vona, G.; Estepa, L.; Béroud, C.; Damotte, D.; Capron, F.; Nalpas, B.; Mineur, A.; Franco, D.; Lacour, B.; Pol, S.; et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004, 39, 792–797. [CrossRef]
143. Fan, S.T.; Yang, Z.F.; Ho, D.W.Y.; Ng, M.N.P.; Yu, W.C.; Wong, J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study. Ann. Surg. 2011, 254, 569–576. [CrossRef]
146. Zhou, H.; Guo, J.-M.; Lou, Y.-R.; Zhang, X.-J.; Zhong, F.-D.; Jiang, Z.; Cheng, J.; Xiao, B.-X. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. *J. Mol. Med.* 2010, 88, 709–717. [CrossRef]

147. Hiraiwa, K.; Takeuchi, H.; Hasegawa, H.; Saikawa, Y.; Suda, K.; Ando, T.; Kumagai, K.; Irino, T.; Yoshikawa, T.; Hatake, K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. *Cancer Sci.* 2010, 101, 1067–1071. [CrossRef]

148. Matsusaka, S.; Chin, K.; Ogura, M.; Suenaga, M.; Shinozaki, E.; Mishima, Y.; Terui, Y.; Mizunuma, N.; Hatake, K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. *Cancer Sci.* 2010, 101, 1067–1071. [CrossRef]

149. Shoda, K.; Masuda, K.; Ichikawa, D.; Arita, T.; Miyakami, Y.; Watanabe, M.; Konishi, H.; Imoto, I.; Otsuji, E. HER2 amplification detected in the circulating DNA of patients with gastric cancer: A retrospective pilot study. *Gastric Cancer* 2015, 18, 698–710. [CrossRef]

150. Mimori, K.; Fukagawa, T.; Kosaka, Y.; Ishikawa, K.; Iwatsuki, M.; Yokobori, T.; Hirasaki, S.; Takatsuno, Y.; Sakashita, H.; Ishii, H.; et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. *Ann. Surg. Oncol.* 2008, 15, 2934–2942. [CrossRef]

151. Del Re, M.; Tiseo, M.; Bordi, P.; D’Incecco, A.; Camerini, A.; Petrini, I.; Lucchesi, M.; Inno, A.; Spada, D.; Vasile, E.; et al. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA. *Oncotarget* 2017, 8, 13611–13619. [CrossRef]

152. Sozzi, G.; Roz, L.; Conte, D.; Mariani, L.; Andriani, F.; Lo Vullo, S.; Verri, C.; Pastorino, U. Plasma DNA quantification in lung cancer computed tomography screening: Five-year results of a prospective study. *Am. J. Respir. Crit. Care Med.* 2009, 179, 69–74. [CrossRef]

153. Tognela, A.; Spring, K.J.; Becker, T.; Caixeiro, N.J.; Bray, V.J.; Yip, P.Y.; Chua, W.; Lim, S.H.; de Souza, P. Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician’s perspective. *Crit. Rev. Oncol. Hematol.* 2015, 93, 90–102. [CrossRef]

154. Hiltermann, T.J.N.; Pore, M.M.; van den Berg, A.; Timens, W.; Boehzen, H.M.; Liesker, J.J.W.; Schouwink, J.H.; Wijnands, W.J.A.; Kerner, G.S.M.A.; Kruyt, F.A.; et al. Circulating tumor cells in small cell lung cancer: A predictive and prognostic factor. *Ann. Oncol.* 2012, 23, 2937–2942. [CrossRef]

155. Tanaka, F.; Yoneda, K.; Kondo, N.; Hashimoto, M.; Takuwa, T.; Matsumoto, S.; Okumura, Y.; Rahman, S.; Tsubota, N.; Tsujimura, T.; et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. *Clin. Cancer Res.* 2009, 15, 6980–6986. [CrossRef]

156. Ying, M.; Zhu, X.-X.; Zhao, Y.; Li, D.-H.; Chen, L.-H. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials. *Asian Pac. J. Cancer Prev.* 2015, 16, 4439–4445. [CrossRef]

157. Camps, C.; Jantus-Lewintre, E.; Cabrera, A.; Blasco, A.; Sanmartí, E.; Gallach, S.; Caballero, C.; del Pozo, N.; Rosell, R.; Guijarro, R.; et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. *Lung Cancer* 2011, 72, 365–369. [CrossRef]
162. Gallo, M.; De Luca, A.; Maiello, M.R.; D’Alessio, A.; Esposito, C.; Chicchinelli, N.; Forgione, L.; Piccirillo, M.C.; Rocco, G.; Morabito, A.; et al. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. *Transl. Lung Cancer Res.* **2017**, *6*, 486–498. [CrossRef]

163. Thress, K.S.; Paweletz, C.P.; Felip, E.; Cho, B.C.; Stetson, D.; Dougherty, B.; Lai, Z.; Markovets, A.; Vivancos, A.; Kuang, Y.; et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M. *Nat. Med.* **2015**, *21*, 560–562. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).